LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why

Zacks Investment Research highlights LeMaitre Vascular (LMAT) as a compelling growth stock, citing its favorable Growth Score (B) and Zacks Rank #2 (Buy). The medical device maker is projected to see 17.2% EPS growth this year, significantly outpacing the industry average of 11.4%, alongside robust year-over-year cash flow growth of 35.1% compared to the industry's 1.2%. Furthermore, positive earnings estimate revisions, with current-year estimates surging 5.6% over the past month, underpin its potential for outperformance, making it a solid consideration for growth-oriented investors.

Analysis

LeMaitre Vascular (LMAT) is presented as a compelling growth opportunity based on a proprietary scoring system that highlights strong fundamental momentum. The company's projected EPS growth for the current year stands at 17.2%, significantly outpacing the medical device industry's average forecast of 11.4%. This earnings trajectory is supported by robust cash flow generation, with year-over-year growth of 35.1% dwarfing the industry average of 1.2% and an annualized 3-5 year cash flow growth rate of 18.1% that is more than double the industry's 8%. Critically, forward-looking sentiment appears positive, as evidenced by a 5.6% upward revision in the Zacks Consensus Estimate for current-year earnings over the past month. This combination of superior earnings growth, strong cash accumulation, and positive analyst revisions has earned the stock a Zacks Rank #2 (Buy) and a Growth Score of B, positioning it as a potential outperformer in its sector.

Key Decisions for Investors

• Given the combination of double-digit projected EPS growth and superior cash flow generation relative to its industry, growth-oriented investors should consider LMAT a strong candidate for inclusion in their portfolios.
• The 5.6% upward revision in current-year earnings estimates over the last month suggests positive near-term momentum, providing a basis for current shareholders to maintain or potentially add to their positions.
• Investors should closely monitor upcoming earnings reports to verify that LMAT's actual performance aligns with the projected 17.2% EPS growth, as this is a key pillar of the current investment thesis.